38749-90-5

Usage

Uses

Used in Chemical Synthesis:
Pyridine, 5-bromo-2-ethyl-, is used as a key intermediate in the synthesis of various organic compounds and pharmaceuticals. Its reactivity with electrophiles and nucleophiles allows for the formation of a wide range of derivatives, making it a valuable building block in organic chemistry.
Used in Research Applications:
In the field of scientific research, Pyridine, 5-bromo-2-ethyl-, serves as a versatile compound for studying various chemical reactions and mechanisms. Its unique structure and properties make it an ideal candidate for exploring new reaction pathways and developing novel synthetic methods.
Used in Pharmaceutical Industry:
Pyridine, 5-bromo-2-ethyl-, is utilized in the development of pharmaceutical drugs, particularly in the synthesis of active pharmaceutical ingredients (APIs). Its ability to form various derivatives and its compatibility with different chemical reactions make it a promising candidate for the creation of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, Pyridine, 5-bromo-2-ethyl-, is employed in the synthesis of various agrochemical products, such as pesticides and herbicides. Its reactivity and structural diversity contribute to the development of effective and targeted agrochemicals for crop protection and management.
Used in Material Science:
Pyridine, 5-bromo-2-ethyl-, also finds applications in the field of material science, where it is used in the development of new materials with specific properties. Its ability to form complexes and interact with other molecules makes it a valuable component in the creation of advanced materials for various applications, such as sensors, catalysts, and functional coatings.

InChI:InChI=1/C7H8BrN/c1-2-7-4-3-6(8)5-9-7/h3-5H,2H2,1H3

Upstream product

• 100-71-0 2-Ethylpyridine 
• 624-28-2 2,5-dibromopyridine 
• 557-20-0 diethylzinc 
• 223463-13-6 2-iodo-5-bromopyridine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 111770-80-0 3-bromo-6-(trimethylsilylethynyl)pyridine 
• 111770-86-6 2-ethynyl-5-bromo-pyridine 

Downstream Products

• 1083329-19-4 2-ethyl-5-benzyloxypyridine 
• 1571134-70-7 1-[1-(5-cyanopyridin-2-yl)ethyl]-2-methyl-4-oxo-2′-trifluoromethyl-1,4-dihydro[3,4′]bipyridinyl-5-carboxylic acid methylamide 
• 1571135-49-3 1-[1-(5-bromopyridin-2-yl)ethyl]-2-methyl-4-oxo-2′-trifluoromethyl-1,4-dihydro[3,4′]bipyridinyl-5-carboxylic acid methylamide 
• 1571134-71-8 (R)-1-[1-(5-cyanopyridin-2-yl)ethyl]-2-methyl-4-oxo-2‘-trifluoromethyl-1,4-dihydro-[3,4']bipyridinyl-5-carboxylic acid methylamide 
• 1571134-72-9 (S)-1-[1-(5-cyanopyridin-2-yl)ethyl]-2-methyl-4-oxo-2‘-trifluoromethyl-1,4-dihydro-[3,4']bipyridinyl-5-carboxylic acid methylamide 
• 1001907-69-2 (6-ethylpyridin-3-yl)boronic acid 
• 16881-90-6 2-Ethyl-5-vinyl-pyridin 

Relevant academic research and scientific papers

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, e

BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to bicyclic pyrrole derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example. Type II diabetes mellitus.

BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Bicyclic pyrrole derivatives useful as agonists of GPR120

The present invention is directed to bicyclic pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.

UREA INHIBITORS OF MAP KINASES

Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein.

A simple Cu-catalyzed coupling approach to substituted 3-pyridinol and 5-pyrimidinol antioxidants

(Chemical Equation Presented) A convenient approach to 3-pyridinols and 5-pyrimidinols via a two-step Cu-catalyzed benzyloxylation/catalytic hydrogenation sequence is presented. The corresponding 3-pyridinamines and 5-pyrimidinamines can be prepared in an analogous sequence utilizing benzylamine in lieu of benzyl alcohol. The radical-scavenging ability of these derivatives are preliminarily explored and reveal that the increased acidities of the pyridinols and pyrimidinols render them susceptible to more significant kinetic solvent effects when compared to phenols.

Triazole antifungal agents

PCT No. PCT/EP96/02470 Sec. 371 Date Dec. 19, 1997 Sec. 102(e) Date Dec. 19, 1997 PCT Filed Jun. 5, 1996 PCT Pub. No. WO97/01552 PCT Pub. Date Jan. 16, 1997The invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ar, Z and Het are as defined herein. The compounds of formula (I) possess activity as antifungal agents. The invention also relates to pharmaceutical compositions containing said compounds of formula (I) and to methods of treating fungal infections by administering said compounds of formula (I).

Triazole antifungal agents

An antifungal compound of formula (I): STR1 or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R1 is phenyl substituted with 1 to 3 substituents each independently selected from halo and CF3 ; R2 is (hydroxy)C1 -C4 alkyl, CONH2, S(O)m (C1 -C4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF3 ; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C1 -C4 alkyl or (C1 -C4 alkoxy)methyl.